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Clinical research in Latin America and Argentina: 
time for a change
Investigación clínica en América Latina y Argentina: 
¿es tiempo de cambios?
Ugalde and Homedes’s article (1)
discusses the dichotomy between risks, benefits
and science versus the financial interests involved
in clinical trials conducted in developing countries,
in particular in Latin America. The authors make
reference to the limitations clinical trials have in
showing the efficacy and safety of their
interventions. Apart from the relevant limitations
mentioned in the article, such as the small
proportion of drugs proven useful in practice, the
need for a large number of patients, the placebo
effect and adherence complications, there is
publication bias. Not only preclinical studies but
also clinical trials with negative results go
unpublished, frequently leading to a duplication of
efforts. In other words, not only do acts of fraud,
errors, protocol violations or descriptions of the
poor quality with which trials are implemented
remain unmentioned when trial results are
disclosed, but also, in agreement with the authors,
scientific journals are usually less willing to accept
studies with negative results. If the negativity of the
results was not owing to a lack of statistical power,
it is important for the medical and scientific
community to have knowledge of them. 
Other limitations are related to the size of
the sample. In addition to the limitations
mentioned by the authors, many trials are not
powerful enough to show a significant statistical
difference, making it unethical to randomly assign
participants to trials with a small chance of
demonstrating a benefit, if even such a benefit
exists (2). More globally, another limitation which
should be mentioned is the setting of the clinical
research agenda by the pharmaceutical industry,
not always in response to health priorities,
especially those of developing countries.
Nonetheless, inclusion of research centers in
developing countries in order to increase the
number of participants has accelerated notoriously
in recent years. On the other hand, the cost and
regulatory requirements demanded of independent
researchers to conduct a clinical trial make it
extremely difficult – not only in Latin American
countries but also at a global level – to carry out
research projects in areas of potential benefit for the
population, but with little likelihood of producing
financial benefits. In spite of these limitations,
clinical trials are still the best source of evidence to
show the efficacy and effectiveness of
interventions, although the experimental design
may not be the most appropriate for some types of
interventions (for example, non-pharmacological
and public health interventions).
The authors make reference to protocol
violations, fraud and errors that are not reported
and may later bias the results. Delays in reporting
the results in some cases could also be added to the
list, which further limits or may even make
unreliable the results. The article (1) describes the
case of rofecoxib; other similar examples can be
added, such as the case of roziglitazone, a drug for
the treatment of diabetes (3).  
With regards to the ethics committees in
Argentina, capacities at the national level are
being increased by way of national regulatory
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provisions – the National Administration of Drugs,
Food and Medical Technology (ANMAT, from the
Spanish Administración Nacional de Medica-
mentos, Alimentos y Tecnología Médica) Provision
6677/10 (4), Act 3301 of the City of buenos Aires
(5) and other provincial regulations – as well as by
way of work to improve the quality and capacity of
research ethics committees through provincial
initiatives and the ANMAT federal project. These
regulatory provisions require that committees be
accredited and properly trained. However, as the
authors state, many ethics committees lack the
capacity to monitor the clinical trials they have
authorized: most simply perform an initial
evaluation of each protocol. Another barrier to
transparency that could improve committee
evaluation and monitoring strategies is the
publication and communication among com-
mittees, not just of the decisions regarding the
initial evaluation, but also of other information that
could be relevant throughout the course of the
trials. The monitoring of clinical trials is carried out
by the trial sponsors or by companies hired by the
sponsors, with little or no participation from the
local committees. The new regulations in Argentina
give greater importance to local research ethics
committees from each research center, assigning
them monitoring tasks concerning trial quality and
safety, although many of them still do not have the
capacity to take on such tasks. 
With regards to the comments made
about informed consent documents, it is true that
most do not include information adapted to the
participants’ comprehension level, resulting in doc-
uments that are difficult for participants to
understand. It is also important to carry out and
document correctly the process of obtaining in-
formed consent, in which it must be clear that the
potential participant understands the purpose of the
clinical trial, the risks involved, what his or her
participation implies, and who is liable in the case
of damages caused as a consequence of the trial, as
well as his or her right to consider participating, ask
questions, and refuse to participate or withdraw
consent during the trial without suffering
consequences in his or her medical care. As the
authors mention, the inclusion of vulnerable
populations, the use of coercion and the provision
of incomplete information threaten the participants’
autonomy and should be subject to close scrutiny
by all existing control mechanisms. Furthermore,
all personnel involved should receive appropriate
training. Regarding the regulatory agencies, as the
authors explain, it is important that they be more
involved in monitoring clinical trials, though many
times a lack of human resources limits their ability
to carry out this role. 
Given the lack of transparency
surrounding all of the clinical trial control
mechanisms described, patient safety and free
participation in the studies should prevail over any
scientific or commercial interests. The control
mechanisms should be interconnected and share a
common goal.
In Argentina several regulatory pro-
visions, such as Act 3301 in the City of buenos
Aires (5), have taken into account the fact that most
clinical trials do not benefit developing countries,
in which the drug will not be commercialized, or if
commercialized will be unaffordable to the poorest
populations. However, the enactment of this
provision does not put an end to the discussion
regarding economic benefits versus scientific
benefits for future patients. It is true, as the authors
state, that therapeutic options are increasingly
limited, and finding innovative drugs capable of
outperforming all therapeutic strategies considered
current health care standards is becoming more
and more difficult. This has sparked the appearance
of clinical trials that study the effect of drugs whose
absolute potential benefits are small as well as the
proliferation of non-inferiority trials, which are
sometimes justified by the more favorable profile of
the new drug, but often provide no clear benefit
other than introducing a new drug comparable to
one already available on the market.  
This last argument may serve as
another element to support clinical research
carried out by independent researchers or local
institutions, which can attempt to provide
answers to questions relevant at a local level,
and not necessarily related to registering new
drugs or indications. Nevertheless, as mentioned
previously, the capacity of Latin American
countries and the conditions of the research
environment mentioned by the authors with
regards to the researchers (or “participating
physicians”) has meant that this field has been
poorly developed, especially in the area of
clinical medicine.
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Ugalde and Homedes highlight the need
to stimulate clinical research in developing
countries adapted to local needs. Unfortunately, in
the present there are insufficient funds, funding
mechanisms and political will – especially in Latin
America – to promote independent clinical re-
search, or research projects initiated by researchers.
In developed countries, funds made available
through grants and often provided by the gov-
ernment make these projects possible. but even in
developed countries, the clinical research envi-
ronment makes it difficult to carry out this type of
trials. Although some researchers outside of the
developed countries gain access to this funding,
more active national policies are needed, as
Ugalde and Homedes assert. Many potential
researchers take part in clinical trials promoted by
the pharmaceutical industry, which means a
considerable source of income for many of them.
Consequently, this may discourage their par-
ticipation in studies that may be more relevant at a
local level and that require more participation of
professionals from each institution regarding the
design, analysis, and especially, the use of the
findings. With regards to the capacities of the
research ethics committees, particularly in
Argentina, opportunities exist to strengthen the
committees and allow them the possibility to
decide the relevance (at a national or global level)
and the risks and benefits of each clinical trial,
although there still is a long way to go. Many health
care facilities do not have such committees, or do
not safeguard the time members must spend on
committee matters, nor do they provide members
with sufficient institutional support. Given this
scenario, it is difficult to know whether in the short
term these committees will be able to assume the
responsibility of assessing the relevance of each
study, and, even more importantly, to establish
institutional monitoring mechanisms, which
require more time and resources than protocol
approval, but without its financial benefits.
In agreement with the conclusion Ugalde
and Homedes offer, clinical research is crucial for
the progress of different therapeutic areas.
However, the scientific and medical community
should, after this period of proliferation of clinical
trials, develop a critical view regarding the
relevance of each study, not only at a local level,
but also in the contribution of new knowledge and
in benefit of future patients. This will nevertheless
be a difficult task, given the potential conflicts
arising from the different interests at play and the
power inequalities among those involved. 
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